trial · primary record
Enfortumab vedotin
Bladder Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 70 |
| Primary completion | 2031-11-01 |
| Primary endpoint | 2-Year Metastasis-Free Survival (MFS) |
| Registry ID | NCT07908979 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:43:47.062Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07908979
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Enfortumab Vedotin · compound